


Receipt date: 01/22/2007

10575023 - GAU 1623



I hereby certify that this paper (along with any paper referred to as being attached
(enclosed)) is not deposited with the U.S. Postal Service on the date shown
below, but is being deposited as First Class Mail, in an envelope addressed to:
Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Dated: January 19, 2007

Signature:

Nabeela R. McMillan
(Nabeela R. McMillan)

Docket No.: 30986/41933
(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Marco Mastrodonato

Application No.: 10/575,023

Confirmation No.: 7048

Filed: April 7, 2006

Art Unit: Not Yet Assigned

For: Topical Compositions Comprising Telmestaine
for Treating Dermatological Disorders

Examiner: Not Yet Assigned

INFORMATION DISCLOSURE STATEMENT (IDS)

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Sir:

Pursuant to 37 CFR 1.56, 1.97 and 1.98, the attention of the Patent and Trademark Office is hereby directed to the references listed on the attached PTO/SB/08. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the references be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

This Information Disclosure Statement is filed before the mailing date of a first Office Action on the merits as far as is known to the undersigned (37 CFR 1.97(b)(3)).

In accordance with 37 CFR 1.98(a)(2)(ii), Applicant has not submitted copies of U.S. patents and U.S. patent applications. Applicant submits herewith copies of foreign patents and non-patent literature in accordance with 37 CFR 1.98(a)(2).

In accordance with 37 CFR 1.97(g), the filing of this Information Disclosure Statement shall not be construed to mean that a search has been made or that no other material information as defined in 37 CFR 1.56(a) exists. In accordance with 37 CFR 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an

Application No.: 10/575,023

Docket No.: 30986/41933

admission that any patent, publication or other information referred to therein is "prior art" for this invention unless specifically designated as such.

It is submitted that the Information Disclosure Statement is in compliance with 37 CFR 1.98 and the Examiner is respectfully requested to consider the listed references.

The Director is hereby authorized to charge any deficiency in the fees filed, asserted to be filed or which should have been filed herewith (or with any paper hereafter filed in this application by this firm) to our Deposit Account No. 13-2855, under Order No. 30986/41933. A duplicate copy of this paper is enclosed.

Dated: January 19, 2007

Respectfully submitted,

By 
Nabeela R. McMillian

Registration No.: 43,363
MARSHALL, GERSTEIN & BORUN LLP
233 S. Wacker Drive, Suite 6300
Sears Tower
Chicago, Illinois 60606-6357
(312) 474-6300
Attorney for Applicant

Form PTO-1449 (Modified)	Atty. Docket No. 30986/41933	Serial No. 10/575,023
INFORMATION DISCLOSURE STATEMENT	Applicant(s) Marco Mastrodonato	
	Filing Date April 7, 2006	Art Unit Not Yet Assigned

**U.S. PATENT DOCUMENTS**

Examiner Initials	Document Number	Issue or Publication Date	Name	Class	Subclass	Filing Date (If Appropriate)

FOREIGN PATENT DOCUMENTS

Examiner Initials	Document Number	Publication Date	Country	Translation Yes No

OTHER DOCUMENTS

/ESO/	British Journal of Dermatology 1996; 135: pp 533-537; Psoriasis in the community; prevalence, severity and patients' beliefs and attitudes towards the disease; Authors: G. J. Nevitt et al.
/ESO/	Psoriasis; Epidemiology of Psoriasis; Vol. 13, Number 4, October 1995, pp 717-722; Author: Robert S. Stern, MD;
/ESO/	Journal of Clinical Pharmacy and Therapeutics (2000) 25, 1-10; Review Article; Therapeutic strategies for psoriasis; Author: D. M. Ashcroft et al. © 2000 Blackwell Science Ltd.
/ESO/	Article; the Carcinogenic Risk of Treatments for Severe Psoriasis; Authors: Robert S. Stern, M.D. and Nan Laird, Ph.D.; Accepted for Publication Jan. 31, 1994
/ESO/	Special Article; Methotrexate in psoriasis: Revised guidelines; pp 145-156 Authors: Henry H. Roenigk et al.
/ESO/	Article: Drug Therapy; Vol. 332, No. 9; Review Article; Alastair J. J. Wood, M.D., Editor; Treatment of Psoriasis; Authors: Malcolm W. Greaves et al.; Website: www.nejm.org
/ESO/	Article: New Methods of Drug Delivery; Author: Robert Langer; pp 1527-1533; Dated: September 28, 1990

EXAMINER: /Eric Olson/	DATE CONSIDERED: 04/03/2009
------------------------	-----------------------------